Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.

[1]  Meilin Liu.  Chinese expert consensus on the diagnosis and treatment of hypertension in the elderly (2017) , 2018, Aging medicine (Milton (N.S.W)).

[2]  S. Gosselin,et al.  Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. , 2018, CJEM.

[3]  S. Rabkin.  Considerations in Understanding the Coronary Blood Flow- Left 
Ventricular Mass Relationship in Patients with Hypertension , 2016, Current cardiology reviews.

[4]  D. Wood,et al.  The Impact of Left Ventricular Mass on Diastolic Blood Pressure Targets for Patients With Coronary Artery Disease. , 2016, American journal of hypertension.

[5]  Lenore J Launer,et al.  Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. , 2016, JAMA.

[6]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[7]  F. McAlister,et al.  Epidemiology of Hypertension in Canada: An Update. , 2016, The Canadian journal of cardiology.

[8]  P. McFarlane,et al.  Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.

[9]  S. Yusuf,et al.  Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[10]  A. Jamalian,et al.  Lifestyle Modifications to Prevent and Control Hypertension. , 2016, Iranian journal of kidney diseases.

[11]  F. Messerli,et al.  Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. , 2016, Journal of the American College of Cardiology.

[12]  M. Woodward,et al.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.

[13]  Isla Mackenzie,et al.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.

[14]  Anne Forster,et al.  Cluster Randomized Controlled Trial , 2015, Stroke.

[15]  J. Kostis,et al.  Head-to-Head Comparisons of Hydrochlorothiazide With Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects , 2015, Hypertension.

[16]  L. Brewster,et al.  Effects of Thiazide-Type and Thiazide-Like Diuretics on Cardiovascular Events and Mortality: Systematic Review and Meta-Analysis , 2015, Hypertension.

[17]  Faha,et al.  Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. , 2014, Circulation.

[18]  E. McGlynn,et al.  Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. , 2013, Mayo Clinic proceedings.

[19]  Martin McKee,et al.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.

[20]  M. Woodward,et al.  Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. , 2013, The New England journal of medicine.

[21]  Simon L Bacon,et al.  The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.

[22]  H. Parise,et al.  Initial Combination Therapy Reduces the Risk of Cardiovascular Events in Hypertensive Patients: A Matched Cohort Study , 2013, Hypertension.

[23]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[24]  W. Elliott,et al.  What is the prevalence of resistant hypertension in the United States? , 2012, Current opinion in cardiology.

[25]  K. Eagle,et al.  The United States Registry for Fibromuscular Dysplasia: Results in the First 447 Patients , 2012, Circulation.

[26]  Lawrence A Leiter,et al.  The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. , 2012, The Canadian journal of cardiology.

[27]  B. Sherrill,et al.  Single‐Pill vs Free‐Equivalent Combination Therapies for Hypertension: A Meta‐Analysis of Health Care Costs and Adherence , 2011, Journal of clinical hypertension.

[28]  G. Mancia,et al.  Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice , 2011, Hypertension.

[29]  Simon L Bacon,et al.  The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. , 2011, The Canadian journal of cardiology.

[30]  M. Tremblay,et al.  Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades , 2011, Canadian Medical Association Journal.

[31]  J. Banegas,et al.  Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.

[32]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[33]  S. Bangalore,et al.  J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. , 2010, European heart journal.

[34]  C. Cannon,et al.  What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?: Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial , 2010, Circulation.

[35]  R. Lanzman,et al.  Fibromuscular dysplasia in living renal donors: still a challenge to computed tomographic angiography. , 2010, European journal of radiology.

[36]  L. Trinquart,et al.  Efficacy of Revascularization For Renal Artery Stenosis Caused by Fibromuscular Dysplasia: A Systematic Review and Meta-Analysis , 2010, Hypertension.

[37]  Simon L Bacon,et al.  The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. , 2010, The Canadian journal of cardiology.

[38]  Alexander G Logan,et al.  The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy , 2009 .

[39]  M. Vandervoort,et al.  A Simplified Approach to the Treatment of Uncomplicated Hypertension: A Cluster Randomized, Controlled Trial , 2009, Hypertension.

[40]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[41]  A. Lumsden,et al.  The long-term outcomes of percutaneous therapy for renal artery fibromuscular dysplasia. , 2008, Journal of vascular surgery.

[42]  D. Goff,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[43]  Lawrence A Leiter,et al.  The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. , 2008, The Canadian journal of cardiology.

[44]  Daniel W. Jones,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[45]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[46]  Lawrence A Leiter,et al.  The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. , 2007, The Canadian journal of cardiology.

[47]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[48]  E. Schiffrin,et al.  The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. , 2006, The Canadian journal of cardiology.

[49]  Lawrence A Leiter,et al.  The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. , 2006, The Canadian journal of cardiology.

[50]  F. McAlister.  The Canadian Hypertension Education Program--a unique Canadian initiative. , 2006, The Canadian journal of cardiology.

[51]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[52]  Alexander G Logan,et al.  The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. , 2005, The Canadian journal of cardiology.

[53]  S. Textor.  Pitfalls in Imaging for Renal Artery Stenosis , 2004, Annals of Internal Medicine.

[54]  J. V. van Engelshoven,et al.  Accuracy of Computed Tomographic Angiography and Magnetic Resonance Angiography for Diagnosing Renal Artery Stenosis , 2004, Annals of Internal Medicine.

[55]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[56]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[57]  J. Olin,et al.  Fibromuscular dysplasia. , 2004, The New England journal of medicine.

[58]  O. Shoheiber,et al.  Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. , 2003, Congestive heart failure.

[59]  N J Wald,et al.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.

[60]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[61]  B. Davis,et al.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). , 2002, Journal of clinical hypertension.

[62]  E. Schiffrin,et al.  The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. , 2002, The Canadian journal of cardiology.

[63]  E. Schiffrin,et al.  The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. , 2002, The Canadian journal of cardiology.

[64]  M. Mauro,et al.  Incidence of donor renal fibromuscular dysplasia: does it justify routine angiography? , 2002, Transplantation.

[65]  F. McAlister,et al.  The 2000 Canadian recommendations for the management of hypertension: part two--diagnosis and assessment of people with high blood pressure. , 2001, The Canadian journal of cardiology.

[66]  R. Hirose,et al.  Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. , 2000, Radiology.

[67]  L. Appel,et al.  Effect of dietary patterns on ambulatory blood pressure : results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. , 1999, Hypertension.

[68]  C. Champagne,et al.  Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension Trial. DASH Collaborative Research Group. , 1999, Journal of the American Dietetic Association.

[69]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[70]  J. Riehl,et al.  Renal artery stenosis: evaluation with colour duplex ultrasonography. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[71]  G. Bray,et al.  A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. , 1997, The New England journal of medicine.

[72]  W. Kannel.  Blood pressure as a cardiovascular risk factor: prevention and treatment. , 1996, JAMA.

[73]  J. Olin,et al.  The Utility of Duplex Ultrasound Scanning of the Renal Arteries for Diagnosing Significant Renal Artery Stenosis , 1995, Annals of Internal Medicine.

[74]  G. T. Shaw,et al.  Incidental fibromuscular dysplasia in potential renal donors: long-term clinical follow-up. , 1989, Radiology.

[75]  K. Mettinger.  Fibromuscular dysplasia and the brain. II. Current concept of the disease. , 1982, Stroke.

[76]  O. Salvatierra,et al.  Results and significance of angiography in potential kidney donors. , 1979, Radiology.

[77]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[78]  Simon L Bacon,et al.  The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2014, The Canadian journal of cardiology.

[79]  Lawrence A Leiter,et al.  The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.

[80]  E. Schiffrin,et al.  The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk. , 2010, The Canadian journal of cardiology.

[81]  D. Wald,et al.  Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials , 2010 .

[82]  E. Schiffrin,et al.  The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. , 2009, The Canadian journal of cardiology.

[83]  E. Schiffrin,et al.  The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. , 2006, The Canadian journal of cardiology.

[84]  E. Schiffrin,et al.  The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. , 2005, The Canadian journal of cardiology.

[85]  E. Schiffrin,et al.  The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. , 2004, The Canadian journal of cardiology.

[86]  F. McAlister,et al.  The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. , 2004, The Canadian journal of cardiology.

[87]  J. Olin,et al.  Fibromuscular dysplasia. , 2012, Circulation.

[88]  A. Logan,et al.  The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension. , 2004, The Canadian journal of cardiology.

[89]  Orton,et al.  EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION ( DASH ) DIET , 2000 .

[90]  R B Haynes,et al.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.